5BR-ADB-INACA Powder
€ 35,90 – € 895,00Price range: € 35,90 through € 895,00
5BR-ADB-INACA Powder is described as a research material associated with a brominated indazole-3-carboxamide structure.
The supplied source identifies the compound as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1H-indazole-3-carboxamide and places it within the broader analytical context of synthetic cannabinoid-related compounds.
The reported presentation is a white to off-white crystalline powder intended for controlled, non-clinical laboratory investigation.
Relevant scientific contexts include chemical identity assessment, structural characterization, analytical documentation, and comparison with related indazole carboxamides.
The source claims ingredient purity of at least 98%, HPLC verification, third-party testing, batch traceability, and supporting Certificates of Analysis.
No actual batch-specific analytical records were supplied to substantiate these claims.
The reported solubility, thermal behavior, UV absorbance, detection limits, hygroscopicity, and storage stability are also unverified.
No independently confirmed CAS Registry Number, molecular formula, molecular weight, or stereochemical specification was provided.
The material is not established as a certified reference material or validated quantitative calibration standard.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
5BR-ADB-INACA Powder – Brominated Indazole Research Material
5BR-ADB-INACA Powder – Product Overview
5BR-ADB-INACA Powder is the supplied catalog designation for a research material described as a brominated indazole-3-carboxamide.
The source places the compound within the analytical context of synthetic cannabinoid-related indazole derivatives.
The reported molecular structure contains an indazole ring system, a bromine substituent, and a carboxamide-containing side chain.
The source describes the product as a white to off-white crystalline powder intended for controlled analytical and non-clinical laboratory research.
The stated scientific contexts include chemical identity assessment, structural characterization, analytical comparison, and documentation of related indazole carboxamide compounds.
These research contexts should not be confused with verified analytical performance of the actual product batch.
The source describes the material as high purity and refers to third-party verification and batch-specific documentation.
However, no actual laboratory report, Certificate of Analysis, reference spectrum, or batch record was supplied.
The reported physical presentation, chemical identity, purity, and stability therefore remain supplier-provided claims.
The material is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.
Chemical Identity & Classification
The supplied source identifies the named compound as 5BR-ADB-INACA.
It describes the material as a brominated indazole-3-carboxamide associated with synthetic cannabinoid analog research.
The supplied chemical information includes:
- Catalog designation: 5BR-ADB-INACA Powder
- Reported chemical name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1H-indazole-3-carboxamide
- Reported chemical family: Brominated indazole-3-carboxamide
- Structural features: Indazole ring, bromine substituent, and carboxamide-containing side chain
- CAS Registry Number: Not supplied
- Molecular formula: Not independently verified
- Molecular weight: Not independently verified
- Reported presentation: Crystalline powder
- Intended designation: Research Use Only
The supplied chemical name provides a proposed structural description.
However, no independent structural record was supplied to establish that the catalog designation and systematic name refer to the same verified chemical entity.
The source does not establish the actual salt form, hydrate or solvate status, or stereochemical composition of the material.
These distinctions may affect definitive chemical identification and interpretation of analytical results. 5BR-ADB-INACA Powder
The reported chemical family should not be interpreted as proof of a particular pharmacological mechanism or potency.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the actual molecular structure and chemical form.
Chemical & Physical Characteristics
The supplied source describes the product as white to off-white crystalline powder.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
The reported appearance therefore remains a supplier-provided description.
The named structure contains a brominated indazole ring system and carboxamide functionality.
These structural features distinguish it from non-brominated indazole carboxamides and compounds with different aromatic substitution patterns.
The source reports a calculated lipophilicity value of cLogP 2.8 and a topological polar surface area of 94.4 Ų.
No computational method, structural calculation record, or independently verified source was provided for these values.
The source also reports thermal decomposition above 250°C and UV absorbance maxima at approximately 225 and 292 nm.
No thermogravimetric report, thermal analysis record, or UV spectrum was supplied.
The source provides numerical solubility claims for methanol, DMSO, and acetonitrile.
No experimental solubility report or solvent-specific validation record was provided.
Consequently, these values should not be published as verified specifications.
The source also does not establish the crystalline polymorph, particle-size distribution, hygroscopicity, or validated stability profile of the actual batch.
Purity & Analytical Verification
The supplied source claims ingredient purity of at least 98% by HPLC.
It also refers to analytical verification using mass spectrometry and NMR spectroscopy.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed purity and analytical identity therefore remain unverified.
For 5BR-ADB-INACA Powder, chemical identity, purity, and intended analytical application should be distinguished from demonstrated quantitative reference suitability.
The source reports analytical detection performance down to 0.1 ng/mL.
However, no validated method, calibration record, matrix specification, detection-limit study, or supporting instrument report was supplied.
That figure cannot be presented as an established detection limit for the product or for a general analytical method. 5BR-ADB-INACA Powder
The source also describes use in analytical comparison and method validation.
No certified reference-material documentation, assigned reference value, measurement-uncertainty statement, or metrological traceability record was provided.
The material should therefore not be described as a certified quantitative reference standard.
Any definitive claims about purity, identity, analytical sensitivity, impurity levels, or reference suitability require supporting records.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, and controlled production conditions.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, or certification was supplied.
The claims therefore remain unverified.
For reproducible analytical documentation, relevant records may include verified chemical identifiers, confirmed chemical form, stereochemical composition where available, batch number, analytical findings, receipt date, and available storage history. 5BR-ADB-INACA Powder
The source does not establish independently verified purity, crystalline morphology, residual-solvent limits, powder homogeneity, or batch-to-batch equivalence.
For 5BR-ADB-INACA Powder, the distinction between source-reported specifications and independently verified analytical findings is particularly important.
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, manufacturing controls, impurity limits, and batch consistency should be supported by actual records.
Safety, Handling & Laboratory Precautions
The source places 5BR-ADB-INACA within a chemical family associated with synthetic cannabinoid research.
Compounds in this broader category may present significant toxicological hazards, and the specific safety profile of the supplied material has not been established.
No complete product-specific toxicological assessment or verified Safety Data Sheet was supplied.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
Fine powders can introduce additional concerns involving accidental dispersal and unintended exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical identity, ingredient purity, and physical characteristics have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings. 5BR-ADB-INACA Powder
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes resealable packaging and nominal quantity options of 500 mg, 1 g, and 5 g.
No current product inventory record, verified pack-size specification, or packaging-validation report was supplied.
These quantities should therefore be treated as source-reported options rather than confirmed availability.
The source recommends storage at approximately -20°C in a desiccated, light-protected environment.
It also claims low hygroscopicity and extended crystalline stability.
No validated product-specific stability study, moisture-sorption report, or storage-condition verification was supplied.
For 5BR-ADB-INACA Powder, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
The source does not establish a validated shelf life or confirm that the recommended storage conditions preserve the actual material over a defined period.
Intended Research Use & Market Positioning
The supplied scientific context places 5BR-ADB-INACA within analytical research involving indazole carboxamide chemical identity, bromine substitution, and comparative structural characterization.
The brominated indazole ring system and carboxamide-containing side chain provide distinguishing structural features relevant to chemical analysis.
The source describes interest in chromatographic characterization, spectroscopic identification, and comparison with related synthetic cannabinoid-associated compounds.
However, no product-specific analytical validation, biological activity dataset, or stability study was supplied for the actual powder.
The Raw Lab Chems catalog identifies 5BR-ADB-INACA Powder as the product listing discussed here.
For related catalog context, the supplied source also identifies ADB-BUTINACA and 6-CL-ADBA.
These related listings concern separate chemical designations and should not be treated as chemically identical to 5BR-ADB-INACA.
The supplied information does not establish equivalent chemical identity, purity, chemical form, or analytical performance across these products.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes international shipping, temperature-controlled transport, tracking, and supporting compliance documentation.
No current inventory record, carrier agreement, temperature-validation report, shipment authorization, or verified delivery information was supplied.
The source also claims compliance with IATA requirements.
No applicable dangerous-goods classification, shipping declaration, or transport-compliance documentation was provided to substantiate that claim.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
Synthetic cannabinoid-related compounds may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
5BR-ADB-INACA is described as a brominated indazole carboxamide associated with synthetic cannabinoid research.
Its possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction and confirmed chemical identity.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (grams) |
2 ,5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.